Cargando…
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?
The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. Consistent data have recently shown the important role of the PI3...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570519/ https://www.ncbi.nlm.nih.gov/pubmed/18797463 http://dx.doi.org/10.1038/sj.bjc.6604636 |